Literature DB >> 23334350

The comparison of the impact of ghrelin and tacrolimus on vitreous cytokine levels in an experimental uveitis model.

Fatih Cem Gül1, Burak Turgut, Ferda Dağlı, Nevin Ilhan, Metin Özgen.   

Abstract

BACKGROUND: We aimed to compare the effects of intraperitoneal ghrelin and tacrolimus on vitreous levels of tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6) in an experimental autoimmune uveitis model.
METHODS: Twenty-four male rats, each weighing 300 g, were assigned into four groups, six rats in each. All the rats, except for those in group 1, were injected intravitreally with concanavalin a to induce experimental uveitis. The development of uveitis was confirmed by the histopathologic examination of two rat globes from each group. The rats in group 2 were not given any treatment after uveitis was induced. The rats in group 3 were administered 1 mg/kg/day of intraperitoneal tacrolimus on days 0, 1, 3, 5 and 7 following the induction of uveitis (on the 14th day of study). The rats in group 4 were given 10 ng/kg/day of intraperitoneal ghrelin for 7 days following the induction of uveitis. On the 21st day of the study, all rats were sacrificed, and the eyes enucleated were subjected to histopathologic examination. Vitreous levels of TNF-α, IL-1 and IL-6 were measured by the enzyme-linked immunosorbent assay method.
RESULTS: The histopathologic evaluation carried out to confirm the development of uveitis revealed destruction in the retinae and ciliary bodies of the immunized rats. The mean vitreous levels of TNF-α, IL-1 and IL-6 were significantly higher in the sham group than in the control group (p < 0.05). The levels of these three cytokines showed a significant decrease in the tacrolimus treatment group (p < 0.05). Cytokine levels decreased in the ghrelin treatment group relative to the control group; however, the decrease was not found statistically significant (p > 0.05).
CONCLUSIONS: Tacrolimus could be effective in uveitis treatment by neutralizing or decreasing the levels of cytokines such as TNF-α, IL-1 and IL-6 that have a critical part in the pathogenesis of uveitis. However, ghrelin failed to produce the desired effect. Further studies using different doses and different ways of administration are needed to determine the effective dose of ghrelin in uveitis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23334350     DOI: 10.1007/s00417-013-2259-x

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  54 in total

Review 1.  The growth hormone secretagogue receptor.

Authors:  M Korbonits; E Ciccarelli; E Ghigo; A B Grossman
Journal:  Growth Horm IGF Res       Date:  1999-04       Impact factor: 2.372

2.  Ghrelin induces adiposity in rodents.

Authors:  M Tschöp; D L Smiley; M L Heiman
Journal:  Nature       Date:  2000-10-19       Impact factor: 49.962

Review 3.  Ghrelin: structure and function.

Authors:  Masayasu Kojima; Kenji Kangawa
Journal:  Physiol Rev       Date:  2005-04       Impact factor: 37.312

4.  Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents.

Authors:  R K Saurenmann; A V Levin; B M Feldman; R M Laxer; R Schneider; E D Silverman
Journal:  J Pediatr       Date:  2006-12       Impact factor: 4.406

5.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach.

Authors:  M Kojima; H Hosoda; Y Date; M Nakazato; H Matsuo; K Kangawa
Journal:  Nature       Date:  1999-12-09       Impact factor: 49.962

Review 6.  Uveitis: what do we know and how does it help?

Authors:  S Lightman
Journal:  Clin Exp Ophthalmol       Date:  2001-04       Impact factor: 4.207

7.  FK506 inhibits prostaglandin E2 production from synovial cells by suppressing peripheral blood mononuclear cells.

Authors:  Tatsuya Sasakawa; Yuka Sasakawa; Yoshitaka Ohkubo; Seitaro Mutoh
Journal:  Int Immunopharmacol       Date:  2005-04-21       Impact factor: 4.932

8.  Aqueous humor interleukin-6 levels in uveitis.

Authors:  P I Murray; R Hoekzema; M A van Haren; F D de Hon; A Kijlstra
Journal:  Invest Ophthalmol Vis Sci       Date:  1990-05       Impact factor: 4.799

9.  FK506 treatment of noninfectious uveitis.

Authors:  M Ishioka; S Ohno; S Nakamura; K Isobe; N Watanabe; Y Ishigatsubo; S Tanaka
Journal:  Am J Ophthalmol       Date:  1994-12-15       Impact factor: 5.258

10.  Regulatory effects of IFN-β on the development of experimental autoimmune uveoretinitis in B10RIII mice.

Authors:  Min Sun; Yan Yang; Peizeng Yang; Bo Lei; Liping Du; Aize Kijlstra
Journal:  PLoS One       Date:  2011-05-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.